Currently, molecular networks of estrogenic signaling via ERα, ERβ, and GPR30 in PCa have not been fully understood but new compounds, whose efficacy has been successfully tested in preclinical and clinical models of PC, opened the way for novel therapeutic strategies for treating prostatic diseases (41, 59). This evidence concerns the gene ESR2 and prostate disorder.